Anatumomab mafenatox

Drug Profile

Anatumomab mafenatox

Alternative Names: ABR 214936; PNU 214936; TTS CD2

Latest Information Update: 04 Oct 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Active Biotech
  • Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 10 May 2004 Discontinued - Phase-I for Non-small cell lung cancer in Europe (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Non-small cell lung cancer in USA (unspecified route)
  • 10 May 2004 Discontinued - Phase-II for Pancreatic cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top